Clinical Trial Detail

NCT ID NCT01742988
Title Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Curis, Inc.
Indications

non-Hodgkin lymphoma

B-cell lymphoma

diffuse large B-cell lymphoma

Hodgkin's lymphoma

Therapies

Bendamustine + CUDC-907 + Rituximab

CUDC-907 + Rituximab

CUDC-907

CUDC-907 + Venetoclax

Age Groups: adult senior

No variant requirements are available.